Cargando…

ET-8 Integrated diagnostic approach to predict prognosis for malignant gliomas

Previous studies indicated that MGMT promoter methylation status with IDH and TERT promotor mutation are major prognostic factors in glioma. In addition to these molecular features, we have been assessing drug sensitivity against several chemotherapeutic agents, including temozolomide (TMZ). Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isoda, Masataka, Tateishi, Kensuke, Sasame, Jo, Hayashi, Takahiro, Miyake, Youhei, Oshima, Akito, Honma, Hirokuni, Yamamoto, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648208/ http://dx.doi.org/10.1093/noajnl/vdab159.018

Ejemplares similares

GEN-8 Real-time PCR based intraoperative genetic analysis for gliomas
por: Takabayashi, Katsuhiro, et al.
Publicado: (2021)

ET-1 Translational research platform for malignant brain tumors
por: Tateishi, Kensuke, et al.
Publicado: (2021)

SPDR-1 HSP90 inhibition overcomes resistant to molecular targeted therapy in BRAF(V600E) mutant glioblastoma
por: Sasame, Jo, et al.
Publicado: (2021)

SPDR-01 Paired epithelioid glioblastoma patient-derived xenograft models to evaluate resistant mechanism for molecular target therapy
por: Sasame, Jo, et al.
Publicado: (2020)

CS-03 BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young
por: Hayashi, Takahiro, et al.
Publicado: (2020)

CBMS-04 Novel xenograft model to clarify tumor progressive mechanism and therapeutic target in primary central nervous system lymphoma
por: Tateishi, Kensuke, et al.
Publicado: (2020)

HGG-51. PAIRED EPITHELIOID GLIOBLASTOMA PATIENT DERIVED XENOGRAFT MODELS WITH/WITHOUT MOLECULAR TARGET THERAPY
por: Sasame, Jo, et al.
Publicado: (2020)

Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma
por: Tateishi, Kensuke, et al.
Publicado: (2023)

TB-04 TERT PROMOTER MUTATION AS A SUSCEPTIBLE MOLECULAR MARKER OF BCNU LOCAL THERAPY
por: Miyake, Shigeta, et al.
Publicado: (2019)

BT-07 PATIENT DERIVED XENOGRAFT MODELS OF EPITHELIOID GLIOBLASTOMA AND THERAPEUTIC VULNERABILITY IN MOLECULAR TARGET THERAPY
por: Sasame, Jo, et al.
Publicado: (2019)

Verbal and memory deficits caused by aphasic status epilepticus after resection of a left temporal lobe glioma
por: Kamogawa, Misaki, et al.
Publicado: (2021)

BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young
por: Tateishi, Kensuke, et al.
Publicado: (2020)

COT-08 Analysis of prognosis of biopsy/partial resection cases of malignant glioma
por: Yamamoto, Yohei, et al.
Publicado: (2020)

ET-7 EVALUATION OF HYPOXIA-TARGETING RADIOPHARMACEUTICAL(64)CU-ATSM FOR PET MONITORING WITH LOCAL THERAPY IN HIGH-GRADE GLIOMA MODEL
por: Yoshii, Yukie, et al.
Publicado: (2022)

Thiel’s embalming method with additional intra-cerebral ventricular formalin injection (TEIF) for cadaver training of head and brain surgery
por: Miyake, Shigeta, et al.
Publicado: (2020)

TB-02 NF-KB CANONICAL PATHWAY ACTIVATION DRIVES GLYCOLYSIS AND TUMOR PROGRESSION IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Tateishi, Kensuke, et al.
Publicado: (2019)

ET-03 Convection-enhanced delivery of EZH2 inhibitor for the treatment of diffuse midline glioma
por: Sasaki, Takahiro, et al.
Publicado: (2020)

A case of midbrain germinoma: A literature review for radiographic and clinical features
por: Miyake, Yohei, et al.
Publicado: (2023)

ET-06 Suppression of glioblastoma through novel drug based on “Gene Switch Technology”
por: Yamamoto, Etsuko, et al.
Publicado: (2020)

ET-6 Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

BT-1 An autopsy case of multicentric malignant glioma, H3K27M mutant
por: Hayashi, Nobuhide, et al.
Publicado: (2021)

CBMS-05 Biological and Pathological meaning of aneuploidy in mouse glioma stem sell
por: Negoto, Tetsuya, et al.
Publicado: (2020)

IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma
por: Akasaki, Yasuharu, et al.
Publicado: (2021)

TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
por: Lita, Adrian, et al.
Publicado: (2021)

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

STMO-7 Usefulness of NU-KNIT in retractorless surgery for malignant glioma
por: Yamanaka, Yuji, et al.
Publicado: (2021)

DDRE-18. THE MITOCHONDRIAL PYRUVATE CARRIER—A METABOLIC TARGET OF MALIGNANT GLIOMA
por: Tiburcio, Patricia, et al.
Publicado: (2021)

ET-9 Development of photosensitive antibodies for near-infrared light immunotherapy targeting EGFR and IL13Rα2 of malignant gliomas and investigation of their photodynamic cytotoxic activity in vitro
por: Nonoguchi, Naosuke, et al.
Publicado: (2021)

ACT-5 Prognosis of IDH-mut lower-grade gliomas in Hokkaido University Hospital
por: Yamaguchi, Shigeru, et al.
Publicado: (2021)

Superficial siderosis and nonobstructive hydrocephalus due to subependymoma in the ventricle: An illustrative case report
por: Otomo, Yuta, et al.
Publicado: (2021)

STMO-01 Cerebral edema and perioperative epilepsy due to placement of BCNU wafer for malignant glioma
por: Fujii, Yu, et al.
Publicado: (2020)

MPC-4 Malignant transformation of diffuse low-grade gliomas: systematic review and meta-analysis
por: Nakasu, Satoshi, et al.
Publicado: (2021)

ET-04 Enhancing drug delivery with MRI-guided focused ultrasound for diffuse intrinsic pontine glioma model
por: Ishida, Joji, et al.
Publicado: (2020)

NI-3 Magnetic resonance relaxometry for tumor cell density imaging for glioma: An exploratory study via 11C-methionine PET and its validation via stereotactic tissue sampling
por: Kinoshita, Manabu, et al.
Publicado: (2021)

MPC-2 Clinical course and prognosis of lower-grade glioma, IDH wildtype and pTERT mutant
por: Takahashi, Yoshinobu, et al.
Publicado: (2021)

ETMM-06. ELEVATED MITOCHONDRIAL TOM20 EXPRESSION SUPPRESSES GLIOMA MALIGNANCY BY ENHANCING OXIDATIVE PHOSPHORYLATION
por: Li, Mao, et al.
Publicado: (2021)

ACT-8 Current status and prospects for the treatment of malignant glioma using cancer gene panel tests
por: Koizumi, Shinichiro, et al.
Publicado: (2021)

NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
por: Sanada, Takahiro, et al.
Publicado: (2021)

NI-7 Diffusion-weighted imaging for monitoring acute response and recurrence after photodynamic therapy in malignant gliomas
por: Fujita, Yuichi, et al.
Publicado: (2021)

GEN-09 Pursuing the function of microRNA targeting (Pro)renin receptor against glioma
por: Ogawa, Daisuke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_52fgigqlpmt9macr8h6b78pchm